Focus: Life Molecular Imaging is a Berlin-based biotech specializing in molecular imaging agents for neurology, oncology, and cardiovascular diseases. The company operates as a pre-revenue or early-stage biotech focused on PET tracers and diagnostic imaging.
Profile data last refreshed 1h ago · AI intelligence enriched 2mo ago
No open roles listed right now. Follow Life Molecular Imaging to get notified when they start hiring — the background below is worth knowing for when they do.
Automated analysis based on publicly available data (FDA, SEC, ClinicalTrials.gov). May be incomplete or delayed. This score does not reflect insider knowledge and should not be used as the sole basis for investment or employment decisions.
Help build intelligence for Life Molecular Imaging
No one has shared interview or compensation data for this company yet. You'll earn 7 days of Pro access.
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.
Generated by Claude from Life Molecular Imaging's SEC filings, pipeline programs, hiring velocity, FDA actions, and WARN data. Inference, not editorial — verify before quoting.
CMS and FDA Announce RAPID Coverage Pathway to Accelerate Patient Access to Life-Changing Medical Devices
CMS and FDA announce the Regulatory Alignment for Predictable and Immediate Device (RAPID) coverage pathway, a new pathway designed to expedite access to certain FDA-designated Class II and Class III Breakthrough Devices for people with Medicare.
8-K Filing: Lantheus Holdings, Inc. (LNTH) (CIK 0001521036) — EX-99.1
EX-99.1
No open positions listed yet. Check their careers page directly.
Upgrade to Pro to access AI interview prep brief and other premium pharma intelligence.
Upgrade to Pro — $25/moBased on last 4 crawl cycles
Recent peer-reviewed publications with author affiliations at this company
First human whole-body biodistribution and dosimetry analysis of [(18)F]LW223, a novel TSPO PET radiotracer.
Self-reported sleep quality and longitudinal amyloid burden in clinically unimpaired adults from the AMYPAD PNHS study.
Showing 5 of 10 publications